BridgeBio Oncology rises on Fast Track status for pancreatic cancer asset
Summary
BridgeBio Onmcology's BBO-11818 wins FDA Fast Track designation for KRAS-mutant pancreatic cancer. Read more here.
Description
BridgeBio Onmcology's BBO-11818 wins FDA Fast Track designation for KRAS-mutant pancreatic cancer. Read more here.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source